Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort

Greeve, I; Sellner, J; Lauterburg, T; Walker, U; Rösler, KM; Mattle, HP; Swiss, Cohort (2007). Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort. Acta neurologica Scandinavica, 116(4), pp. 207-10. Oxford: Blackwell Munksgaard 10.1111/j.1600-0404.2007.00872.x

Full text not available from this repository. (Request a copy)

OBJECTIVES: In patients with a clinically isolated syndrome (CIS), the time interval to convert to clinically definite multiple sclerosis (CDMS) is highly variable. Individual and geographical prognostic factors remain to be determined. Whether anti-myelin antibodies may predict the risk of conversion to CDMS in Swiss CIS patients of the canton Berne was the subject of the study. METHODS: Anti-myelin oligodendrocyte glycoprotein and anti-myelin basic protein antibodies were determined prospectively in patients admitted to our department. RESULTS: After a mean follow-up of 12 months, none of nine antibody-negative, but 22 of 30 antibody-positive patients had progressed to CDMS. Beta-Interferon treatment delayed the time to conversion from a mean of 7.4 to 10.9 months. CONCLUSIONS: In a Swiss cohort, antibody-negative CIS patients have a favorable short-term prognosis, and antibody-positive patients benefit from early treatment.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology
UniBE Contributor:	Greeve, Isabell, Rösler, Kai Michael, Mattle, Heinrich
ISSN:	0001-6314
ISBN:	17824895
Publisher:	Blackwell Munksgaard
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 14:55
Last Modified:	05 Dec 2022 14:17
Publisher DOI:	10.1111/j.1600-0404.2007.00872.x
PubMed ID:	17824895
Web of Science ID:	000249220700002
URI:	https://boris.unibe.ch/id/eprint/23473 (FactScience: 41941)